Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $61.30 Consensus Target Price from Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $61.30.

Several research analysts have recently weighed in on IMCR shares. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. UBS Group set a $55.00 price target on shares of Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. Mizuho set a $38.00 price objective on shares of Immunocore in a research report on Thursday, February 19th. Needham & Company LLC boosted their target price on shares of Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st.

Immunocore Trading Down 0.2%

Shares of NASDAQ IMCR opened at $33.34 on Friday. The company has a quick ratio of 4.01, a current ratio of 4.04 and a debt-to-equity ratio of 1.03. Immunocore has a 12 month low of $23.15 and a 12 month high of $40.71. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -47.63 and a beta of 0.78. The business has a fifty day simple moving average of $33.06 and a 200-day simple moving average of $34.36.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The company had revenue of $104.48 million during the quarter, compared to analysts’ expectations of $145.48 million. During the same period in the prior year, the business posted ($0.47) EPS. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. Sell-side analysts predict that Immunocore will post -0.94 EPS for the current year.

Insider Activity at Immunocore

In related news, CEO Bahija Jallal sold 11,474 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $371,183.90. Following the completion of the sale, the chief executive officer directly owned 12,343 shares of the company’s stock, valued at approximately $399,296.05. This represents a 48.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David M. Berman sold 5,965 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the sale, the insider owned 5,859 shares of the company’s stock, valued at $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 19,137 shares of company stock valued at $619,082. Company insiders own 10.40% of the company’s stock.

Institutional Trading of Immunocore

Several institutional investors have recently made changes to their positions in IMCR. Bellevue Group AG increased its stake in Immunocore by 99.9% in the 2nd quarter. Bellevue Group AG now owns 2,441,830 shares of the company’s stock valued at $76,625,000 after buying an additional 1,220,036 shares during the period. Primecap Management Co. CA boosted its stake in shares of Immunocore by 40.8% during the 2nd quarter. Primecap Management Co. CA now owns 3,771,474 shares of the company’s stock valued at $118,349,000 after buying an additional 1,092,824 shares during the period. BVF Inc. IL purchased a new position in shares of Immunocore during the 2nd quarter valued at $32,142,000. Millennium Management LLC increased its stake in shares of Immunocore by 334.3% in the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after acquiring an additional 974,463 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new position in shares of Immunocore in the fourth quarter worth $20,305,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.